Dr. Joachim Kohn
NJ Center for Biomaterials, United Sates of America
Dr. Joachim Kohn, Director of the NJ Center for Biomaterials, is a leader in biomaterials science and widely known for the development of tyrosine-derived, resorbable polymers, which are now used in several FDA-approved medical devices. Currently about 250,000 patients in the USA, Canada, Latin America, and Europe are using implants containing tyrosine-derived, resorbable polymers which are being commercialized by REVA Medical, TYRX, Bard, and Medtronic. Dr. Kohn's current research efforts focus on the development of new discovery paradigms for revolutionary biomaterials using combinatorial and computational methods to optimize the composition, properties, and cellular responses of biomaterials for specific applications, particularly tissue engineering and drug delivery. Dr. Kohn has published extensively, including over 200 major, peer-reviewed publications, 40 book chapters, and over 70 issued US patents. Many of his recent publications focus on methods to control the behavior of cells (including stem cells) in the context of regenerative medicine. Examples of this work include research on mandibular jaw bone regeneration using human dental cell-seeded scaffolds (J of Tissue Engineeering, Part A, 2016, 22(13/14), 985-993), mitochondria-targeted nanoparticles for selective growth inhibition of lung cancer (ACS App Mat Interfaces, 2016, 8(39), 25680-25690), generation and brain–transplantation of 3-D microscale networks of reprogrammed human neurons (Nature Communications, 2016, 7, 10862), and cytoskeleton-based forecasting of stem cell lineage fates (Proc. Natl. Acad. Sci. USA, 2010, 107(2), 610-615). In 2015, Dr. Kohn was appointed as a member of the Roundtable on Biomedical Engineering Materials and Applications of the National Research Council of the National Academy of Sciences. In 2014 he was the recipient of the Research Award from the Health Care Institute of New Jersey for contributions to life sciences and healthcare. In 2013, Kohn was inducted into the National Academy of Inventors. He currently serves as the Elected Chair of the International College of Fellows of Biomaterials Science and Engineering. Since 2008, he directs the Rutgers-Cleveland Consortium of the Armed Forces Institute of Regenerative Medicine (AFIRM), a $50 Million program funded by the Department of Defense. He is also one of the founding members of the ASTM F04 Committee where he participates in the development of industry-wide standards for tissue engineering and regenerative medicine products.